AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when given early during treatment.

Datroway Datopotamabe Deruxtecana O Datroway® (datopotamabe deruxtecana) é um novo medicamento biológico recentemente registrado pela Agênc...

AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat forms of the disease.

China approves Datopotamab Deruxtecan (Datroway) for advanced HR-positive, HER2-negative breast cancer after prior therapy.

The FDA has approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo), a Trop-2−directed antibody and topoisomerase inhibitor conjugate, for adult ...

Learn about Datopotamab Deruxtecan-dlnk (Datroway), its uses, side effects, dosage, and what to expect during treatment.

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in the U.S. and Japan.

The drug is said to have significantly improved survival and delayed disease progression in patients with a particularly hard to treat form of the disease.

A Agência Nacional de Vigilância Sanitária (Anvisa) aprovou, nesta segunda-feira (27), a inclusão de nova indicação terapêutica para o medicamento Datroway® (datopotamabe deruxtecana), desenvolvido pelo laboratório Daiichi Sankyo Brasil Farmacêutica Ltda. A decisão, registrada no Diário Oficial da União conforme a Resolução 2.871/2026, autoriza o uso do produto para adultos com câncer de pulmão de […]

Datroway, developed with AstraZeneca, has been approved for patients with advanced breast tumors.

Paolo Tarantino: Datopotamab Deruxtecan Improves Outcomes in IO-Ineligible mTNBC / Breast Cancer, cancer, datopotamab deruxtecan, Datroway, ESMO25, OncoDaily,

YouTube video by Dr. Rob Swanda

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.

AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.

Datopotamab-Deruxtecan significantly improves overall survival versus chemotherapy in first-line metastatic triple-negative breast cancer.

On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...

Companies’ first-line ambitions for the antibody drug conjugate buoyed by the TROPION-Breast02 clinical trial.

AstraZeneca, Daiichi Sankyo and Gilead report promising trial results in ‘triple negative’ breast cancer

On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...

Daiichi Sankyo and AstraZeneca have moved swiftly to file for approval of TROP2-targeting Datroway for triple-negative breast cancer.

On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...

The FDA on Monday approved AstraZeneca and Daiichi Sankyo’s TROP2-targeting drug Datroway in a new lung cancer indication, broadening the amount of patients for what the company hopes is their next big blockbuster. Datroway is ...